Abingworth invests in €33m round for Epigenomics
Abingworth has invested in listed biotech company Epigenomics AG as part of an oversubscribed €33.1m fundraising round.
Following the transaction, Abingworth will become the largest shareholder in the company.
German Epigenomics AG completed the placement of 14.7 million new ordinary bearer shares, which were placed at the subscription price of €2.25 per new share resulting in gross proceeds of about €33.1 million.
The rights offering started on 15 March and ended on 29 March. ICF Kursmakler AG acted as sole lead manager and sole underwriter.
More on DACH
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
EU FSR could impact PE fundraising with potential rise in ‘clean funds’
FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Redalpine expands leadership team amid CHF 1bn-plus fundraise
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater